Search Results
Photomodulation of lymphatic delivery of liposomes to the brain bypassing the blood-brain barrier: new perspectives for glioma therapy
2021, Semyachkina-Glushkovskaya, Oxana, Fedosov, Ivan, Shirokov, Alexander, Vodovozova, Elena, Alekseeva, Anna, Khorovodov, Alexandr, Blokhina, Inna, Terskov, Andrey, Mamedova, Aysel, Klimova, Maria, Dubrovsky, Alexander, Ageev, Vasily, Agranovich, Ilana, Vinnik, Valeria, Tsven, Anna, Sokolovski, Sergey, Rafailov, Edik, Penzel, Thomas, Kurths, Jürgen
The blood-brain barrier (BBB) has a significant contribution to the protection of the central nervous system (CNS). However, it also limits the brain drug delivery and thereby complicates the treatment of CNS diseases. The development of safe methods for an effective delivery of medications and nanocarriers to the brain can be a revolutionary step in the overcoming this limitation. Here, we report the unique properties of the lymphatic system to deliver tracers and liposomes to the brain meninges, brain tissues, and glioma in rats. Using a quantum-dot-based 1267 nm laser (for photosensitizer-free generation of singlet oxygen), we clearly demonstrate photostimulation of lymphatic delivery of liposomes to glioma as well as lymphatic clearance of liposomes from the brain. These pilot findings open promising perspectives for photomodulation of lymphatic delivery of drugs and nanocarriers to the brain pathology bypassing the BBB. The lymphatic “smart” delivery of liposomes with antitumor drugs in the new brain tumor branches might be a breakthrough strategy for the therapy of gliomas.
Immunophenotyping of Circulating and Intratumoral Myeloid and T Cells in Glioblastoma Patients
2022, Marx, Sascha, Wilken, Fabian, Miebach, Lea, Ispirjan, Mikael, Kinnen, Frederik, Paul, Sebastian, Bien-Möller, Sandra, Freund, Eric, Baldauf, Jörg, Fleck, Steffen, Siebert, Nikolai, Lode, Holger, Stahl, Andreas, Rauch, Bernhard H., Singer, Stephan, Ritter, Christoph, Schroeder, Henry W. S., Bekeschus, Sander
Glioblastoma is the most common and lethal primary brain malignancy that almost inevitably recurs as therapy-refractory cancer. While the success of immune checkpoint blockade (ICB) revealed the immense potential of immune-targeted therapies in several types of cancers outside the central nervous system, it failed to show objective responses in glioblastoma patients as of now. The ability of glioblastoma cells to drive multiple modes of T cell dysfunction while exhibiting low-quality neoepitopes, low-mutational load, and poor antigen priming limits anti-tumor immunity and efficacy of antigen-unspecific immunotherapies such as ICB. An in-depth understanding of the GBM immune landscape is essential to delineate and reprogram such immunosuppressive circuits during disease progression. In this view, the present study aimed to characterize the peripheral and intratumoral immune compartments of 35 glioblastoma patients compared to age- and sex-matched healthy control probands, particularly focusing on exhaustion signatures on myeloid and T cell subsets. Compared to healthy control participants, different immune signatures were already found in the peripheral circulation, partially related to the steroid medication the patients received. Intratumoral CD4+ and CD8+ TEM cells (CD62Llow/CD45ROhigh) revealed a high expression of PD1, which was also increased on intratumoral, pro-tumorigenic macrophages/microglia. Histopathological analysis further identified high PSGL-1 expression levels of the latter, which has recently been linked to increased metastasis in melanoma and colon cancer via P-selectin-mediated platelet activation. Overall, the present study comprises immunophenotyping of a patient cohort to give implications for eligible immunotherapeutic targets in neurooncology in the future.